期刊文献+

溶栓干预犬脑栓塞后血浆u-PA和u-PAR水平变化的实验研究

The levels of u-PA and u-PAR during thrombolysis therapy of canines cerebral embolism:An experimental study
下载PDF
导出
摘要 目的观察尿激酶原(pro-UK)和尿激酶(UK)干预犬脑栓塞后血浆尿激酶型纤溶酶原激活剂(u-PA)和尿激酶型纤溶酶原激活剂受体(u-PAR)的变化,及其与溶栓效果的关系。方法自体动脉血凝固制备栓子,使用介入方法建立犬脑栓塞模型。栓塞2h后,分别用pro-UK和UK溶栓,分为A、B 2组,造影观察血管开通情况;实验前(0 h)、治疗后2h和3h时u-PA和u-PAR的变化。结果犬脑栓塞后2 h给予不同溶栓药处理,2 h后造影证实:A组6只中血管开通5只,B组6只中血管开通2只;A组溶栓后2h、3h血浆u-PA值比溶栓前(0h)升高(P<0.01),且2 h比3 h时u-PA值高(P<0.01);B组溶栓后2h、3h与0h时比较u-PA值无明显变化(P>0.05)。2组间2h、3h时u-PA值比较差异有统计学意义(P<0.01)。2组间和2组内不同时间点血浆u-PAR水平差异无统计学意义(P>0.05)。结论血浆u-PA在一定程度上反映了犬脑栓塞溶栓后纤溶系统的变化,血管开通比例较高,血浆u-PA增高明显。血浆u-PAR在pro-UK、UK溶栓后变化不大,与犬血管开通无明确关系。 Objective To investigate the changes of plasma levels of urokinase-type plasminogen activator(u- PA) and urokinase-type plasminogen activator receptor(u-PAR) with the chugs intervention of pro-UK and urokinase (UK) in cerebral embolism, and to evaluate the relationship between them and thrombolytic effects, Methods A ca- nine thromboembolism model was established through intervention, which injected auto artery blood thrombus into the canines' artery. After 2 hours, the pro-UK and UK was applied in group A and B respectively. All animals were underwent digital subtraction angiography (DSA) examination and evaluated the recanalization of occluded cerebral arteries. The levels of plasma u-PA and u-PAR were detected before thrombeembolism,2 h and 3 h after being treated respectively. Results The DSA resalts showed that 5 of 6 canines had recanalization of occluded cerebral artery 2 hours after intravenous pro-UK in group A; 2 of 6 canines had recanalization of occluded cerebral artery 2 hours after intravenous UK in group B. In group A, the level of u-PA increased gradually after treatment( P 〈 0.01 ), and it showed statistical signifinanee difference between 2 h and 3 h ( P 〈 0.01 ). Otherwise, it didn' t showed statistical signifinanee difference in group B after 2 h and 3 h ( P 〉 0.05). The difference was statistical significance, intravenous pro-UK vs. intravenous UK ( P 〈 0.01 ). The level of u-PAR in different time point didn't showed significant difference compared inter-group and intro-group ( P 〉 0.05). Conclusion The level of plasma u-PA coald represent the changes of fibrinolysis system after thrombolysis in canines thrombeembolism. The plasma u-PA level was high in animal which recanalization. There was no exact relationship between the plasma u-PAR levels and recanalization of occluded cerebral arteries in canines.
出处 《疑难病杂志》 CAS 2008年第8期472-475,共4页 Chinese Journal of Difficult and Complicated Cases
关键词 脑栓塞 尿激酶型纤溶酶原激活剂 尿激酶型纤溶酶原激活剂受体 Cerebral embolism Urokinase-type plasminogen activator Urokinase-type plasminogen activator receptor Canine
  • 相关文献

参考文献16

  • 1Pyke C, IG-istensen P, Ralfkiaer E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas [J]. Am J Pathol, 1991, 138 (5) : 1 059-1 067.
  • 2Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci, 2001, 936 : 226-236.
  • 3Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy[ J]. Cromer Metastasis Rev. 2003,22(2-3) : 205-222.
  • 4Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: amultifunctional role in tumor progression and metastasis [ J]. Clin Orthop Relat Res. 2003, (415 Suppl) : S46-S58.
  • 5Shariat SF, Roehrbom CG, McConnell JD, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastais [J]. J Clin Oncol.2007,25(4) :349-355.
  • 6Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, u-PAR. Stem Cells. 1997,15(6) : 398-408.
  • 7Hosomi N, Lucero J, Heo JH, et al. Rapid differential endogenous plasminogen activator Expression after acute middle cerebral artery occlusion [J]. Stroke,2001,32(6) : 1 341-1 348.
  • 8Chang DI, Hosomi N, Lucero JH, et al. Activation Systems for Latent Matrix Metallopoteinase-2 are upregulated immediately after focal cerebral ischemia[J] .J Cereb Blood Flow Metab,2003,23(12) : 1 408- 1 419.
  • 9刘秀文,孙自勇,窦桂芳,朱镇华,袁守军,陈于红,张菁,刘建宁,汤仲明,刘蓓钫.重组人尿激酶原药代动力学的研究[J].南京大学学报(自然科学版),2001,37(4):435-451. 被引量:10
  • 10Li C, Zhang J, Jiang Y, et al. Urokinase-type plasminogen activator upregulates its own expression by endothelial cells and monocytes via the u- PAR pathway[J]. Thromb Res,2001,103(3) :221-232.

二级参考文献31

  • 1Harrell RL, Rajanayagam S. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation, 1997; 96(2) :621 - 627.
  • 2Bauters C, Isner JM. The biology of restenosis. Prog Cardiovasc Dis, 1997; 40(2): 107-116.
  • 3Schwartz RS. Patheophysiology of resterosis: interactive of thrombosis, hyperplasia and/or remodeling. Am J Carcliol, 1998; 81:14E - 17E.
  • 4Dumler I. Urokinase induces activation and formation of Stat4 and Statl-Stat2 complexes in human vascular smooth muscle cells. J Biol Chem, 1999; 274: 24059-24065.
  • 5Lijnen HR, CoHen D. Matrix metalloproteinase system deficiencies and matrix degradation. Thromb Haemst, 1999; 82: 837-845.
  • 6Christ G, Kosmer K. Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? J Thromb Thrombolysis.1999; 7(3): 277-285.
  • 7Plekhanova OS, Parfyonova YV. Urokinase plasminogen activator enhances neointima growth and reduces lumen size in injured carotid arteries. J Hypertens, 2000; 18(8): 1065-1069.
  • 8Kienast J, Padr6 T. Expression of urokinase-type plasminogen activator in atheroselerotic coronary arteries from human heart explants. Thromb Haemost, 1998; 79: 579-586.
  • 9Plekhanova O. Urokinase plasminogen activator augments cell proliferation and neointima fomation in iniured arteries via protolytic mechanisms. Atherosclerosis, 2001; 159: 297-306.
  • 10Sandip M. Kanse induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arteriosclerosis Thromb Vase Biol, 1997; 17: 2848-2854.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部